Car-T Therapy for Hepatocellular Carcinoma: Recent Advanced Progress
DOI:
https://doi.org/10.54097/tr0x5g28Keywords:
CAR-T cell; Hepatocellular carcinoma; Traditional therapy.Abstract
Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer. Human health is at risk due to the fact that only 10% survive for five years. HCC is treated with surgery, radiotherapy, and chemotherapy as the main methods. However, traditional treatment methods have certain side effects, surgical treatment requires postoperative intensive care, radiotherapy and chemotherapy can damage normal liver tissue, lead to fatigue and nausea and other symptoms, affecting the quality of life of patients. The treatment of hepatocellular carcinoma has been greatly benefited from the development of Chimeric antigen receptor T (CAR-T) cell therapy, which is considered one of the most innovative immunotherapies. Compared to traditional therapies and other immunotherapies, it is highly targeted and can survive and kill tumor cells for a long time. CAR-T cell therapy has become the focus of modern basic medical research and clinical trials. This article reviews the advantages, disadvantages, prospects and challenges of CAR-T cell therapy for liver HCC.
Downloads
References
Anwanwan, D., Singh, S. K., Singh, S., Saikam, V., & Singh, R. Challenges in liver cancer and possible treatment approaches. Biochimica ET biophysica acta. Reviews on cancer, 2020, 1873(1), 188314.
Yu, Y., & Feng, M. Radiotherapy for Hepatocellular Carcinoma. Seminars in radiation oncology, 2018, 28(4), 277–287.
Jiangfan Zhou, Yunfeng Shan. Research progress of immune checkpoint PD-1/PD-L1 inhibitors and CAR-T therapy in hepatocellular carcinoma [J]. J Hepatobiliary and Pancreatic Surgery, 2020, 32(02):65-70+74.
Zheng, X., Liu, X., Lei, Y., Wang, G., & Liu, M. Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma. Frontiers in oncology, 2022, 12, 824208.
Yu, S., Liu, J., Reid, J., Clarke, J., Edwards, S., & Maddern, G. Reoperation for post hepatectomy complications. ANZ journal of surgery, 2023,10.1111/ans.18803.
Sutherland, A. I., IJzermans, J. N., Forsythe, J. L., & Dor, F. J. Kidney and liver transplantation in the elderly. The British journal of surgery, 2016, 103(2), e62–e72.
Chen, W., Chiang, C. L., & Dawson, L. A. Efficacy and safety of radiotherapy for primary liver cancer. Chinese clinical oncology, 2021, 10(1), 9.
Park, S. H., Kim, J. C., & Kang, M. K. Technical advances in external radiotherapy for hepatocellular carcinoma. World journal of gastroenterology, 2016, 22(32), 7311–7321.
Corrao, G., Marvaso, G., Ferrara, R., Lo Russo, G., Gugliandolo, S. G., Piperno, G., Spaggiari, L., De Marinis, F., Orecchia, R., Garassino, M. C., & Jereczek-Fossa, B. A. Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. Lung cancer (Amsterdam, Netherlands), 2020,142, 70–79.
Jeong, S. W., Jang, J. Y., Lee, J. E., Lee, S. H., Kim, S. G., Cha, S. W., Kim, Y. S., Cho, Y. D., Kim, H. S., Kim, B. S., Kim, K. H., & Kim, Y. J. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. Asia-Pacific journal of clinical oncology, 2012, 8(2), 164–171.
Li, K., LAN, Y., Wang, J., & Liu, L. Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine, 2017, 39(3), 1010428317692229.
Chen, Y. J., Abila, B., & Mostafa Kamel, Y. CAR-T: What Is Next? Cancers, 2023, 15(3), 663.
Li, D., Li, N., Zhang, Y. F., Fu, H., Feng, M., Schneider, D., Su, L., Wu, X., Zhou, J., Mackay, S., Kramer, J., Duan, Z., Yang, H., Kolluri, A., Hummer, A. M., Torres, M. B., Zhu, H., Hall, M. D., Luo, X., Chen, J., … Ho, M. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Gastroenterology, 2020, 158(8), 2250–2265.e20.
Labanieh, L., & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature, 2023, 614(7949), 635–648.
Busato, D., Mossenta, M., Baboci, L., Di Cintio, F., Toffoli, G., & Dal Bo, M. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert review of clinical pharmacology, 2019, 12(5), 453–470.
Heczey A. Alliance of the Titans: An Effective Combination of a TKI with CAR T Cells. Molecular therapy: the journal of the American Society of Gene Therapy, 2019, 27(8), 1348–1349.
Yang, C., You, J., Pan, Q., Tang, Y., Cai, L., Huang, Y., Gu, J., Wang, Y., Yang, X., Du, Y., Ouyang, D., Chen, H., Zhong, H., Li, Y., Yang, J., Han, Y., Sun, F., Chen, Y., Wang, Q., Weng, D., … Xia, J. Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma. BMC medicine, 2023, 21(1), 327.
Tang, X., Guo, N., Xu, L., Gou, X., & Mi, M. CD147/EMMPRIN: an effective therapeutic target for hepatocellular carcinoma. Journal of drug targeting, 2013, 21(3), 224–231.
Shen, J., Yang, D., & Ding, Y. Advances in Promoting the Efficacy of Chimeric Antigen Receptor T Cells in the Treatment of Hepatocellular Carcinoma. Cancers, 2022, 14(20), 5018.
Shin, M. H., Oh, E., Kim, Y., Nam, D. H., Jeon, S. Y., Yu, J. H., & Minn, D. Recent Advances in CAR-Based Solid Tumor Immunotherapy. Cells, 2023, 12(12), 1606.
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., Timmerman, J. M., Stiff, P. J., Friedberg, J. W., Flinn, I. W., Goy, A., Hill, B. T., Smith, M. R., Deol, A., Farooq, U., McSweeney, P., … Go, W. Y. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. The New England journal of medicine, 2017, 377(26), 2531–2544.
Carloni, R., Sabbioni, S., Rizzo, A., Ricci, A. D., Palloni, A., Petrarota, C., Cusmai, A., Tavolari, S., Gadaleta-Caldarola, G., & Brandi, G. Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma. Journal of hepatocellular carcinoma, 2023, 10, 1445–1463.
Hongjing Liu, Tieyi Zhou, Xuyan Zhou,et al. Research progress of CAR-T cells targeting GPC3 in the treatment of liver cancer [J]. Journal of Guangxi Medical University, 2023, 40(09):1588-1596.
Lin, H., Cheng, J., Mu, W., Zhou, J., & Zhu, L. Advances in Universal CAR-T Cell Therapy. Frontiers in immunology, 2021, 12, 744823.
Wu, X., Luo, H., Shi, B., Di, S., Sun, R., Su, J., Liu, Y., Li, H., Jiang, H., & Li, Z. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma. Molecular therapy: the journal of the American Society of Gene Therapy, 2019, 27(8), 1483–1494.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
